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In	severe	cases,	ECT	should	be	initiated	within	the	first	five	days	to	lower	
mortality	rates.	Mortality	rates	of	malignant	catatonia	is	20%,	and	response	
rate	is	higher	with	ECT	(89%)	than	lorazepam	alone	(40%).	Recommendation	
is	daily	treatments	of	ECT	for	at	least	six	treatments	to	reduce	risk	of	sudden	
relapse.	ECT	is	terminated	after	the	acute	catatonic	episode,	but	
maintenance	ECT	sessions	have	been	successful	in	treating	periodic	
catatonia.	For	benzodiazepine	treatment,	recommendation	is	to	maintain	the	
dose	for	6	months	then	taper	slowly	to	prevent	relapse.	
	
Psychiatrist	and	Internist	should	work	closely	to	prevent	complications:		
•  Monitor	autonomic	instability	
•  Daily	CK	measurements	
•  Hydration,	nutrition	status:	For	arrhythmia	and	evaluation	for	feeding	tube	
•  Ins/Outs:	For	urinary	retention		
•  Frequent	repositioning:	To	prevent	ulcers,	deep	vein	thrombosis,	
pulmonary	embolism,	contractures	and	aspiration		
Catatonia	should	be	on	a	differential	diagnosis	for	patients	presenting	with	
mental	status	changes	to	ensure	timely	treatment	to	decrease	morbidity	
and	mortality.	Dopamine	blocking	drugs	are	contraindicated	in	malignant	
catatonia	as	they	can	precipitative	and	worsen	catatonia	and	put	a	patient	
at	increase	risk	for	developing	neuroleptic	malignant	syndrome.		
	
There	is	a	need	for	more	ECT	trained	physicians	to	help	decrease	mortality	
of	catatonia	and	to	increase	access	to	a	invaluable	treatment.	With	the	
underdiagnoses	of	catatonia,	further	research	is	warranted	to	aid	in	
diagnosis	and	treatment	of	this	disorder.		
CONCLUSION	
Catatonia	includes	three	or	more	of	the	following	symptoms:	
Symptom	 Description	
Stupor	 No	psychomotor	activity;	not	actively	relating	to	
environment	
Catalepsy	 Passive	induction	of	a	posture	held	against	gravity	
Waxy	
Flexibility	
Slight,	even	resistance	to	positioning	by	examiner;	often	
will	remain	in	the	new	position	
Mutism	 No,	or	very	little,	verbal	response	(exclude	if	known	
aphasia)	
Negativism	 Opposition	or	no	response	to	instructions	or	external	
stimuli	
Posturing	 Spontaneous	and	active	maintenance	of	a	posture	against	
gravity	
Mannerism	 Odd,	circumstantial	caricature	of	normal	actions	
Stereotypy	 Repetitive,	abnormally	frequent,	non-goal-directed	
movements	
Agitation	 Does	not	appear	to	be	influenced	by	external	stimuli	
Grimacing	 Contortion	of	facial	features	
Echolalia	 Mimicking	another’s	speech	
Echopraxia		 Mimicking	another’s	movements		
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Creatine	Kinase	Trend	Over	Time	
On	termination	of	ECT,	he	was	on	valproic	acid	1000mg	two	times	a	day,	
olanzapine	10mg	at	night,	temazepam	15mg	at	night,	and	lorzepam	1	mg	two	times	
a	day	to	help	maintain	control	of	his	symptoms.	After	discharge,	he	was	admitted	
to	our	community	assertiveness	program	and	he	continued	to	do	well	on	his	
medications.	Over	several	months,	his	outpatient	psychiatrist	slowly	tapered	and	
discontinued	the	lorazepam	and	he	continues	to	have	good	control	of	his	mood	
and	psychotic	symptoms	with	no	return	of	catatonia	symptoms.	
A	consult	for	electroconvulsive	therapy	(ECT)	was	
placed	and	initiated	treatment	of	malignant	
catatonia	(figure	4).	He	responded	well	to	six	
sessions	that	occurred	Mon.,	Wed.,	Fri.,	for	two	
weeks	with	total	resolution	of	symptoms	and	
normalization	of	autonomic	instability	and	
creatine	kinase	levels,	as	seen	in	figure	3.		
Due	to	concern	about	medical	
instability,	the	patient	was	transferred	
to	Saint	Francis	Hospital	to	provide	aid	
in	treatment	of	dehydration,	
malnutrition,	and	access	for	further	
medical	interventions	if	necessary.	
With	the	start	of	autonomic	instability	
(blood	pressure	of	184/106)	and	
elevated	creatine	kinase	at	5,506	
(normal	range	less	than	225).	Pt	was	
diagnosed	with	malignant	catatonia.	
First	line	treatment	is	scheduled	lorazepam	doses,	at	6-22	mg	per	day.	Other	
medications	can	be	used	to	restore	GABA-glutamate	imbalance	(Figure	5).	
Catatonia	is	a	disorder	that		affects	both	behavior	and	motor	
functions.	It	is	divided	into	multiple	categories	and	can	be	
hard	to	distinguish	from	other	disorders	(Figure	1).	The	
incidence	of	catatonia	in	psychiatric	inpatient	setting	is	5-20%,	
with	the	most	common	cause	being	bipolar	depression.		
Malignant	catatonia	can	include:	
•  Autonomic	instability	(fever,	hypertension,	tachycardia)	
•  Severe	muscle	rigidity	
•  Nonspecific	lab	findings	of	leukocytosis	and	elevated	
creatinine	kinase	
Catatonia	may	be	associated	with	changes	in	the	cortical-basal	
ganglia-thalamo-cortical	circuit	(Figure	2)	associated	with:	
•  Low	levels	of	gamma-aminobutric	acid	A	(GABA)	
•  Low	dopamine	D2	receptor	binding	
•  High	levels	of	N-methyl-D-asparate	receptors	
Figure	1.	Three	main	subtypes	of	catatonia	(malignant,	retarded,	
excited)	with	differential	diagnosis	(NMS,	delirious	mania,	
periodic	catatonia).		
Figure	2.	Cortical-basal	ganglia-thalamo-cortical	circuit	path.	
https://www.frontiersin.org/articles/10.3389/fnbeh.2016.00059/full	
Figure	3.	Trend	of	CK	level	during	hospitalization.		
Figure	4.	Unilateal	placement	of	electroconvulsive	therapy	probes.	
https://medicine.musc.edu/departments/psychiatry/divisions-and-
programs/divisions/bsl/ect	
Figure	5.	GABA-Glutamate	Imbalance	
http://primarypsychiatry.com/the-pharmacotherapy-of-catatonia/	
